FEATURES OF THE CLINICAL COURSE OF PSORIASIS IN PATIENTS WITH OBESITY
Psoriasis is the most common chronic, genetically determined autoimmune polyetiological inflammatory disease with impaired epidermal proliferation, provoked by exogenous and endogenous factors, and manifested by erythematous and scaly elements, papules and plaques. According to the results of clinical and epidemiological studies, psoriasis affects about 3-4% of the population of our planet, regardless of gender, age, and ethnic group, and the specific gravity of this pathology in the general structure of skin diseases reaches, from the data of different authors, from 1% to 40 %. However, despite the significant incidence of psoriasis and a large amount of research on this problem, there is still no single view of the pathogenesis of this dermatosis. For an objective understanding of the pathogenesis of psoriasis, it is necessary to take into account the insufficiently studied comorbidity of this pathology. Therefore, in the studies of the pathogenesis of psoriasis in recent years, more attention is paid to the impairment of metabolic processes. Recently, an indisputable link between psoriasis and obesity has been proven. Obesity has been found to increase the risk of many diseases, including psoriasis. The literature has broadly highlighted the question of the pathogenetic mechanisms of inflammatory processes in psoriasis and obesity that form a vicious circle at the level of the immune system, which must be broken for the successful treatment of these diseases. In this research, we studied the clinical presentation of the disease, measured anthropometric parameters, determined the grade of obesity by BMI, analyzed the history of life and disease, and conducted clinical and biochemical blood tests. The results of the study revealed that alimentary obesity in patients with psoriasis leads to metabolic disorders, complicating the course of dermatosis, which leads to a worsening of the DLQI of patients, the inefficiency of standard methods of therapy and frequent exacerbations of psoriatic disease. Therefore, the prospect for further research is a more in-depth study of the comorbidity of psoriatic disease, which will identify new targets for the treatment of this dermatosis to prevent complications and more effective treatment of this pathology.
2. Yemchenko Ya, Іscheykіn K, Kaydashev І. Analіz zahvoryuvanostі ta poshirenostі na psorіaz v Ukraїnі ta v Poltavs'kіy oblastі [Analysis of the incidence and prevalence of psoriasis in Ukraine and in the Poltava region]. Aktual'nі problemi suchasnoї medicini: Vіsnik ukraїns'koї medichnoї stomatologіchnoї akademії. 2014; 3 (47):72-76.
3. Yemchenko Ya. Osobennosti klinicheskogo techeniya psoriaza u bol'nyh s soputstvuyuschim metabolicheskim sindromom v zavisimosti ot urovnya sistemnogo vospaleniya [Peculiarities of the clinical course of psoriasis in patients with concomitant metabolic syndrome depending on the level of systemic inflammation]. Georgian Medical News. 2014; 11 (236):43-47.
4. Yemchenko Ya, Ishcheikin K. Deiaki spilni aspekty patohenezu psoriazu ta metabolichnoho syndromu. Svit medytsyny ta biolohi [Some common aspects of the pathogenesis of psoriasis and metabolic syndrome]. 2013; № 1:176-180.
5. Atkinson RL. Could viruses contribute to the worldwide epidemic of obesity Int J Pediat Obes. 2008; 3: Suppl 1: 37-43.
6. Kaydashev IP. Izmenenie obraza zhizni, narushenie energeticheskogo metabolizma i sistemnoe vospalenie kak faktory razvitiya bolezney civilizacii [Lifestyle changes, impaired energy metabolism and systemic inflammation as factors for the development of civilization diseases]. Ukraїns'kiy medichniy chasopis. 2013; 5: 103-108.
7. Babak OYa, Yarmish NV, Shkol'nik VV. Ozhirіnnya yak puskoviy mehanіzm adipocitokіnovogo kaskadu [Obesity as a trigger mechanism of the adipocytokine cascade]. Medicina transportu Ukrainy. 2012; 2: 94-99.
8. Yemchenko Ya. Ozhyrinnia yak komorbidnyi stan pry psoriazi [Obesity as a Comorbid Condition in Psoriasis]. Vіsnik ukraїns'koї medichnoї stomatologіchnoї akademії. 2018; 18 (63):314-319.
9. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: National Institutes of Health. 2000, NIH publication 00-4084.
10. Finlay AY and Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-216.
11. Basra MK, Fenech R, Gatt RM, Salek MS and Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159:997-1035.
12. Fredriksson, T., U. Pettersson. Severe psoriasis—oral therapy with a new retinoid. Dermatologica, 1978, 157(4):238-44. PMID 357213.
13. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) // JAMA. – 2001. – Vol. 285, 19. – P. 2486-2497.
14. Morris P.B., Ballantyne C.M., Birtcher K.K. et al. Review of clinical practice guidelines for the management of LDL-related risk // J. Am. Coll. Cardiol. – 2014. – Vol. 64. – P. 196–206.
This work is licensed under a Creative Commons Attribution 4.0 International License.